Details for Patent: 10,452,815
✉ Email this page to a colleague
Which drugs does patent 10,452,815 protect, and when does it expire?
Patent 10,452,815 protects FINTEPLA and is included in one NDA.
Protection for FINTEPLA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-three patent family members in fifteen countries.
Summary for Patent: 10,452,815
| Title: | Control system for control of distribution of medication |
| Abstract: | A system of controlling distribution of a medication in the treatment or prevention of epilepsy is provided. A central controller of the system has a data store and one or more processors for reading and writing data to the data store. The data store comprises a database of patient records, each patient record having a medication authorization field. The central controller can output an authorization of a first prescription of epilepsy medication to a patient in dependence upon genetic test results for the patient and schedules a subsequent test for the patient prior to authorization of a subsequent prescription of epilepsy medication. Also provided are methods in which the subject systems find use. The systems and methods find use in the treatment of severe subtypes of epilepsy or refractory epilepsy, such as Dravet Syndrome. |
| Inventor(s): | Stewart; Richard Alistair Balfour (Henley-on-Thames, GB), Clarke; Anthony (Berkshire, GB) |
| Assignee: | Zogenix International Limited (Berkshire, GB) |
| Application Number: | 14/867,862 |
|
Patent Claim Types: see list of patent claims | Use; Compound; Device; |
Drugs Protected by US Patent 10,452,815
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | FINTEPLA | fenfluramine hydrochloride | SOLUTION;ORAL | 212102-001 | Jun 25, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,452,815
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015326472 | ⤷ Try a Trial | |||
| Australia | 2020202655 | ⤷ Try a Trial | |||
| Brazil | 112017006219 | ⤷ Try a Trial | |||
| Canada | 2962367 | ⤷ Try a Trial | |||
| China | 107111673 | ⤷ Try a Trial | |||
| European Patent Office | 3201808 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
